Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations
Study Contact Information:
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930 or email
About the Study
This study will look at how well the talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in or other specific genes. NOTE: This study is no longer enrolling patients.
Type of Study
This is an , single arm study.
- In an study, participants will know which medication they are receiving.
- In a single-group assignment study, all study participants will receive the same therapy.
This Study is Open To:
NOTE: This study is no longer enrolling patients.
This Study is NOT Open To:
NOTE: This study is no longer enrolling patients.
What the Study Involves
- Participants will receive orally once per day. Participants will remain on the medication as long as their cancer doesn't progress and they don't experience unacceptable side effects.
- Participants are followed up at 30 days and then every 12 weeks for 1 year.
Study Site
Houston, TX
M D Anderson Cancer Center
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930
Study Contact Information:
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930 or email
Study Contact Information:
Contact: Dr. Sarina A. Piha-Paul by phone: 713-563-1930 or email